open access

Vol 13, No 2 (2018)
Review Papers
Get Citation

Tailored therapy or how to improve effectiveness of treatment and patient’s prognosis. Antihypertensive therapy intensified step-by-step — from monotherapy to single‐pill combinations

Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2018.0027
·
Folia Cardiologica 2018;13(2):150-156.

open access

Vol 13, No 2 (2018)
Review Papers

Abstract

The goal of antihypertensive therapy is to reduce the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular end points including stroke, myocardial infarction, and heart failure. For patients with stage 1 hypertension, it is often reasonable to start with monotherapy. Recent data, however, suggest that the advantages of initial combination treatment may extend to stage 1 hypertension. Available data suggest that about 70–80% of patients will require combination therapy to achieve contemporary blood pressure targets. Rational combination therapy is based on the co-administration at least two antihypertensive agents. Perindopril-based single-pill combinations are associated with a significant improvement in compliance, effective blood pressure-lowering, and reduction long-term incidence of cardiovascular events.

Abstract

The goal of antihypertensive therapy is to reduce the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular end points including stroke, myocardial infarction, and heart failure. For patients with stage 1 hypertension, it is often reasonable to start with monotherapy. Recent data, however, suggest that the advantages of initial combination treatment may extend to stage 1 hypertension. Available data suggest that about 70–80% of patients will require combination therapy to achieve contemporary blood pressure targets. Rational combination therapy is based on the co-administration at least two antihypertensive agents. Perindopril-based single-pill combinations are associated with a significant improvement in compliance, effective blood pressure-lowering, and reduction long-term incidence of cardiovascular events.

Get Citation

Keywords

antihypertensive therapy, monotherapy, fixed combination therapy

About this article
Title

Tailored therapy or how to improve effectiveness of treatment and patient’s prognosis. Antihypertensive therapy intensified step-by-step — from monotherapy to single‐pill combinations

Journal

Folia Cardiologica

Issue

Vol 13, No 2 (2018)

Pages

150-156

DOI

10.5603/FC.2018.0027

Bibliographic record

Folia Cardiologica 2018;13(2):150-156.

Keywords

antihypertensive therapy
monotherapy
fixed combination therapy

Authors

Beata Wożakowska-Kapłon

References (33)
  1. Zdrojewski T, Bandosz P, Szpakowski P. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL-PLUS. W: Postępy w nefrologii i nadciśnieniu tętniczym. Vol II. Medycyna Praktyczna, Kraków 2002: 11–15.
  2. Drygas W, Niklas AA, Piwońska A, et al. Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol Pol. 2016; 74(7): 681–690.
  3. Tykarski A, Widecka K, Narkiewicz K, et al. Leki złożone w terapii nadciśnienia tętniczego w Polsce. Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Arterial Hypertens. 2017; 21(3): 105–115.
  4. Tykarski A, Narkiewicz K, Gaciong Z, et al. Zasady postępowania w nadciśnieniu tętniczym — 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2015; 1: 1–70.
  5. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers, ESC Scientific Document Group . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
  6. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
  7. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16): 2088–2097.
  8. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013; 61(2): 131–142.
  9. Ricci F, Di Castelnuovo A, Savarese G, et al. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis. Int J Cardiol. 2016; 217: 128–134.
  10. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014; 174(5): 773–785.
  11. Brugts JJ, Ferrari R, Simoons ML. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2009; 7(4): 345–360.
  12. Ceconi C, Fox KM, Remme WJ, et al. EUROPA Investigators, PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007; 73(1): 237–246.
  13. Shah AD, Arora RR. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors? Clin Cardiol. 2005; 28(12): 551–555.
  14. Hatala R, Bachanova K, Sidlo R. SYMBIO: results of a longitudinal study of optimized blood pressure lowering therapy with fixed combination perindopril/amlodipine. J Hypertens. 2010; 28: e98–e99.
  15. Nagy VL. Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination. Clin Drug Investig. 2013; 33(7): 469–476.
  16. Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009; 9(3): 135–142.
  17. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
  18. Williams B, O'Rourke M. Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens. 2001; 15(Suppl 1): S69–S73.
  19. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159–2219.
  20. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 [Epub ahead of print].
  21. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017; 33(10): 1783–1787.
  22. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887–1898.
  23. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829–840.
  24. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet. 2001; 358(9287): 1033–1041.
  25. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014; 14(2): 137–145.
  26. Ábrahám G, Dézsi CA. The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: the Results of the PETRA Study. Adv Ther. 2017; 34(7): 1753–1763.
  27. Zdrojewski T, Bandosz P, Rutkowski M, et al. XIV Zjazd Polskiego Towarzystwa Nadciśnienia Tętniczego. Streszczenia. Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce — wyniki badania NATPOL 2011. Nadciśn Tętn. 2014; 18(2): 116–117.
  28. Prejbisz A, Klocek M, Gąsowski J, et al. Trends for beta-blockers use in a large cohort of Polish hypertensive patients — Pol-Fokus Study. Arterial Hypertens. 2015; 19(3): 120–128.
  29. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet. 1999; 353(9146): 9–13.
  30. Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015; 170(6): 1092–1098.
  31. Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015; 170(6): 1092–1098.
  32. Brugts JJ, Bertrand M, Remme W, et al. The treatment effect of an ace-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovasc Drugs Ther. 2017; 31(4): 391–400.
  33. Palatini P, Rosei EA, Casiglia E, et al. Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. J Hypertens. 2016; 34(5): 813–821.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl